Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
-$8,000 |
 |
Anavex Life SciencesAVXL |
-$8,000 |
 |
AmgenAMGN |
-$500 |
 |
Editas MedicineEDIT |
-$8,000 |
 |
Alnylam PharmaceuticalsALNY |
-$8,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat | Mar 14, 2023 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat | Mar 6, 2023 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Dec 6, 2022 | Buy | $1K - $15K |
Who is the latest politician to buy or sell Biomarin Pharmaceutical shares?
Rohit Khanna sold Biomarin Pharmaceutical shares most recently on March 14, 2023.
Which politician has bought the most BMRN stock in the last two years?
Rohit Khanna has bought the most BMRN stock in the last 2 years, with an estimated value of $8,000.
Which politician has sold the most BMRN stock over the last two years?
Daniel S. Goldman has sold the most BMRN stock in the last 2 years, with an estimated value of $8,000.
What is the total value of politicians trading BMRN stock in the last 2 years?
The net value of trades by US politicians for Biomarin Pharmaceutical in the last 2 years is negative, amounting to -$8,000. This suggests that US politicians do not believe in the success of the company for various reasons.
How do insider transactions over the last 2 years reflect on Biomarin Pharmaceutical's market confidence?
Over the last 2 years, insider transactions for Biomarin Pharmaceutical have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Why should individual investors pay attention to the stock transactions of US politicians?
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
